Gaucher Disease Drug Pipeline — PatSnap Eureka
Gaucher Disease Drug Pipeline: Oral SRT and Next-Generation ERT
GBA1 mutations drive glucosylceramide accumulation in macrophages — fuelling a wave of oral substrate reduction agents, pharmacological chaperones, and glycoengineered enzyme replacements. Explore the full innovation landscape with PatSnap Eureka.
GBA1, GCase, and the Lysosomal Substrate Burden
Gaucher disease (GD), the most prevalent lysosomal storage disorder, results from mutations in the GBA1 gene encoding glucocerebrosidase (GCase) — a lysosomal hydrolase that cleaves the beta-glucosidic bond of glucosylceramide (GlcCer). Deficiency results in substrate accumulation in lysosomes of macrophages, giving rise to the characteristic "Gaucher cell."
Unlike most lysosomal hydrolases, GCase is not efficiently targeted to the lysosome via the canonical mannose-6-phosphate (M6P) receptor pathway. Instead, mannose receptor–mediated endocytosis by macrophages is the dominant uptake mechanism for current enzyme replacement therapies (ERTs). This distinction drives much of the engineering effort around the phosphorylation and glycosylation state of recombinant GCase molecules — a finding confirmed by patent filings from Novazyme Pharmaceuticals and Genzyme Glycobiology Research Institute.
A secondary molecular pathology compounds the clinical picture: accumulation of glucosylsphingosine (Lyso-Gb1) — the deacylated form of GlcCer — is associated with complement dysregulation, autophagy disruption, macrophage polarization changes, TGF-β signaling alterations, and endothelial-to-mesenchymal transition (EndMT) leading to fibrosis. This multimodal pathology, identified in a 2022 Asan Medical Center literature record, is the scientific basis for ERT non-responsiveness in atypical GD. Learn more about lysosomal biology from the National Human Genome Research Institute.
The PatSnap life sciences intelligence platform provides deep patent and literature analytics across rare disease pipelines including Gaucher disease and related LSDs.
Four Innovation Axes Reshaping the Gaucher Disease Pipeline
From approved oral agents to glycoengineered enzymes and HSP amplifiers — the GD pipeline spans mechanistically distinct approaches to a single genetic lesion.
GCS Inhibitors — Substrate Reduction Therapy
Small molecule inhibitors of GCS (UDP-glucose:ceramide glucosyltransferase) reduce the flux of glucosylceramide synthesis, alleviating lysosomal substrate burden without requiring enzyme delivery to the lysosome. Miglustat (NB-DNJ) received conditional marketing authorization in Europe and the United States for type 1 GD — the first SRT approval. Multiple Genzyme patent families (CN, 2014–2016) cover structurally distinct GCS inhibitor series. BioMarin Pharmaceutical (CN, 2018) filed a further GCS scaffold distinct from iminosugar series. The Genzyme CD63 biomarker patent (CN, 2025) explicitly names venglustat, eliglustat, and miglustat as active treatment options.
Miglustat: approved · Eliglustat & Venglustat: named as activePharmacological Chaperones — GCase Stabilization
Competitive inhibitors of GCase, at sub-inhibitory concentrations, stabilize misfolded mutant GCase in the ER, facilitating proper trafficking to the lysosome and restoring residual enzymatic activity. This modality is genotype-restricted — applicable primarily to missense mutations producing misfolded but catalytically competent enzyme. Approaches include iminosugar and isofagomine chaperones (Mount Sinai, US 2006), GIZ/PHCA derivatives (Amicus Therapeutics, CN 2007), and arimoclomol (KemPharm/Zevra, 2021–2024) which amplifies HSP70/HSP90 to rescue misfolded GCase via a distinct protein homeostasis mechanism. Yeda Research (IL, 2012) holds IP on a computational 3D-structure-guided compound identification platform.
Arimoclomol: active filings AU, CA, IN (2021–2024)Glycoengineered Recombinant GCase — Enhanced Lysosomal Targeting
Recombinant GCase administered intravenously restores lysosomal enzyme activity via mannose receptor–mediated endocytosis. Next-generation approaches focus on improving lysosomal targeting efficiency through glycoengineering. Novazyme Pharmaceuticals (US, 2003) and Genzyme Glycobiology Research Institute (AU/WO, 2003) describe highly phosphorylated GCase with M6P residues for improved CI-M6PR–mediated uptake. Protalix Biotherapeutics (CN, 2011) discloses plant-cell-derived high-mannose GCase that bypasses costly CHO-cell glycan remodeling. Yeda Research (IL, 2020) covers engineered GCase variants with modified properties beyond glycan optimization. ERT does not cross the blood-brain barrier, limiting utility in types 2 and 3 GD.
Imiglucerase: standard-of-care · Plant-derived GCase: regulatory attentionCD63 & Lyso-Gb1 — Precision Medicine Framework
A Genzyme Corporation patent (CN, 2025) identifies elevated plasma CD63 levels as a quantitative trigger for initiating SRT (venglustat, eliglustat, miglustat) or ERT (imiglucerase), positioning CD63 as a companion diagnostic tool for treatment decisions. A Centogene AG patent (CN, 2022) positions Lyso-Gb1 as a druggable target in its own right — relevant for both GD and Parkinson disease, which shares GBA1 haploinsufficiency as a risk factor. The Asan Medical Center literature record (2022) also highlights ambroxol's potential therapeutic role as a chemical chaperone in atypical GD cases with ERT non-responsiveness.
CD63: companion diagnostic IP · Lyso-Gb1: GD + Parkinson relevancePipeline Analytics: Assignees, Modalities & Filing Activity
Patent filing patterns across the Gaucher disease innovation landscape, derived from PatSnap Eureka dataset analysis (2003–2025).
Key Assignee Patent Portfolio Distribution
Genzyme/Sanofi leads with 6 patent families spanning SRT, ERT, and diagnostics; Orphazyme/KemPharm/Zevra holds 3 families across jurisdictions for arimoclomol.
Patent Filing Activity by Therapeutic Modality
GCS inhibitor (SRT) filings represent the largest cluster in this dataset, with 7 patents spanning 2014–2025; ERT and chaperone modalities each contribute 5 filings.
Convergent Strategies Shaping the Next Generation of GD Therapy
Retrieved patent data signal deliberate co-development strategies that combine modalities to address differential tissue accessibility and ERT non-responsiveness.
SRT + ERT Combination
Multiple Genzyme GCS inhibitor patents explicitly state that GCS inhibitors "can be used alone or in combination with enzyme replacement therapy." This co-development positioning reflects commercial intent to address differential tissue accessibility: ERT for systemic macrophage clearance; oral SRT for CNS-accessible substrate reduction.
Chaperone + ERT Combination
The Asan Medical Center literature record (2022) highlights ambroxol as a chaperone that may potentiate ERT response in atypical GD by correcting misfolded GCase. The Amicus Therapeutics pharmacological chaperone model for Pompe disease (AT2221 co-administered with recombinant GAA) provides a validated cross-indication precedent for this strategy.
Who Is Filing in the Gaucher Disease Space?
Genzyme Corporation (Sanofi) is the most active assignee in this dataset for GD-related assets, with at least three GCS inhibitor patent families (CN, 2014–2016), a CD63 biomarker patent (CN, 2025), and co-ownership of hyperphosphorylated GCase patents as Genzyme Glycobiology Research Institute. Activity spans SRT, ERT, and diagnostic domains. Explore PatSnap's competitive intelligence analytics to track Sanofi's full rare disease portfolio.
Orphazyme A/S / KemPharm Denmark A/S / Zevra Denmark A/S hold active or pending arimoclomol filings across AU, CA, and IN jurisdictions (2021–2024), indicating a broad patent filing strategy and ongoing clinical development. The description of "improved methods" in the CA filing implies iterative clinical protocol optimization.
Amicus Therapeutics holds a GIZ/PHCA chaperone patent for GD (CN, 2007) and is separately active in Pompe disease ERT improvement — signaling cross-platform LSD expertise. Yeda Research and Development Co. Ltd. (Weizmann Institute) contributes two patent filings: a computational drug discovery method (IL, 2012) and a GCase variant patent (IL, 2020). Centogene AG extends its diagnostics expertise into therapeutic target identification via the Lyso-Gb1 patent (CN, 2022). The PatSnap customer case studies demonstrate how biopharma teams use Eureka to monitor competitor filing strategies in rare disease.
For organisations building or monitoring a GD portfolio, PatSnap's enterprise trust and data security framework ensures IP data is handled with the confidentiality required for competitive intelligence workflows. Global patent filing norms in rare disease are further contextualised by WIPO and EPO resources.
What the Patent Landscape Signals for GD Drug Development
Key strategic takeaways derived from retrieved patent and literature data — for IP teams, R&D strategists, and business development professionals.
GCS Inhibition Is the Dominant Oral Modality — But IP Space Is Crowded
GCS inhibition (SRT) is the dominant oral modality, with approved agents (miglustat) and clinically advanced successors (eliglustat, venglustat) already named in the IP landscape. New entrant GCS inhibitor scaffolds must offer significant differentiation in selectivity, CNS penetration, or pharmacokinetic profile to compete. The BioMarin and Genzyme patent families create a layered IP environment that may constrain structural novelty.
Miglustat approved · Eliglustat & Venglustat advancedGlycoengineering of Recombinant GCase Remains an Active Innovation Space
The hyperphosphorylated GCase and plant-derived high-mannose GCase patents demonstrate two distinct manufacturing strategies. IP around M6P content, glycan profile, and uptake efficiency is still being filed, representing a competitive opportunity for biosimilar and next-generation ERT developers. The Yeda Research GCase variant patent (IL, 2020) signals exploration of protein sequence-level engineering beyond glycan optimization.
Plant-derived GCase: manufacturing cost advantageMap GD Competitor IP with PatSnap Eureka
Track assignee filing velocity, claim scope, and combination therapy IP across the full Gaucher disease landscape.
Gaucher Disease Drug Pipeline — Key Questions Answered
Small molecule inhibitors of GCS (UDP-glucose:ceramide glucosyltransferase) reduce the flux of glucosylceramide synthesis, thereby alleviating lysosomal substrate burden. Miglustat (N-butyl-1-deoxynojirimycin; NB-DNJ), an iminosugar-based GCS inhibitor, received conditional marketing authorization in Europe and the United States for type 1 GD — constituting the first SRT approval in the disease space.
Small molecule competitive inhibitors of GCase, when administered at sub-inhibitory concentrations, stabilize misfolded mutant GCase in the endoplasmic reticulum, facilitating proper trafficking to the lysosome and restoring residual enzymatic activity. This modality is genotype-restricted (applicable primarily to missense mutations producing misfolded but catalytically competent enzyme).
ERT does not cross the blood-brain barrier, limiting utility in types 2 and 3 GD. Additionally, accumulation of glucosylsphingosine (Lyso-Gb1) is associated with complement dysregulation, autophagy disruption, macrophage polarization changes, TGF-β signaling alterations, and endothelial-to-mesenchymal transition (EndMT) leading to fibrosis — explaining ERT non-responsiveness in atypical GD.
A Genzyme Corporation patent (CN, 2025) identifies CD63 plasma levels as a biomarker for lysosomal dysfunction and Gaucher disease progression, with utility for guiding treatment selection among SRT agents (venglustat, eliglustat, miglustat) or ERT (imiglucerase).
Arimoclomol is a hydroxylamine derivative that co-induces heat shock proteins (HSPs) — for treating GD. The mechanism involves amplifying the cellular protein quality control machinery (HSP70/HSP90) to rescue misfolded GCase. Multiple patents from Orphazyme A/S (now KemPharm Denmark A/S / Zevra Denmark A/S) across AU, CA, and IN jurisdictions (2021–2024) claim arimoclomol for treating GD.
The Centogene patent (CN, 2022) positions Lyso-Gb1 as a validated druggable target in its own right, relevant for both GD and Parkinson disease, which shares GBA1 haploinsufficiency as a risk factor. The Asan Medical Center literature record identifies Lyso-Gb1 accumulation as associated with complement activation, macrophage polarization shifts, TGF-β pathway engagement, and EndMT/fibrosis — explaining ERT non-responsiveness in atypical disease courses.
Still have questions? Let PatSnap Eureka search the full GD patent and literature database for you.
Ask PatSnap Eureka About GD DrugsAccelerate Your Gaucher Disease R&D Intelligence
Join 18,000+ innovators already using PatSnap Eureka to map rare disease pipelines, track competitor IP, and identify white space in lysosomal storage disorder drug development.
References
- Gaucher Disease Drugs and Methods of Identifying Same — Yeda Research and Development Co. Ltd., 2012, IL
- Glucosylceramide Synthase Inhibitors (2014 filing) — Genzyme Corporation, 2014, CN
- Glucosylceramide Synthase Inhibitors (2016 filing) — Genzyme Corporation, 2016, CN
- Glucocerebroside Synthase Inhibitors (2015 filing) — Genzyme Corporation, 2015, CN
- Glucosylceramide Synthase Inhibitor for Treating Disease — BioMarin Pharmaceutical Inc., 2018, CN
- Glucoimidazole and Polyhydroxycyclohexylamines Derivatives for Treating Gaucher Disease — Amicus Therapeutics, 2007, CN
- Highly Phosphorylated Acid Beta-Glucocerebrosidase — Novazyme Pharmaceuticals, Inc., 2003, US
- Highly Phosphorylated Acid Beta-Glucocerebrosidase — Genzyme Glycobiology Research Institute Inc., 2003, AU
- Highly Phosphorylated Acid Beta-Glucocerebrosidase — Genzyme Glycobiology Research Institute, Inc., 2003, WO
- Production of High-Mannose Proteins Using Plant Culture — Protalix Biotherapeutics, 2011, CN
- High-Mannose Proteins and Methods for Producing High-Mannose Proteins — Shire Human Genetic Therapies, Inc., 2012, CN
- Variants of Beta-Glucocerebrosidase for Use in Treating Gaucher Disease — Yeda Research and Development Co. Ltd., 2020, IL
- Method for Enhancing Mutant Enzyme Activities in Gaucher Disease — Mount Sinai School of Medicine of New York University, 2006, US
- Arimoclomol for Treating Gaucher Disease — KemPharm Denmark A/S, 2021, CA
- Arimoclomol for Treating Gaucher Disease — Orphazyme A/S, 2023, AU
- Arimoclomol for Treating Gaucher Disease — Zevra Denmark A/S, 2024, IN
- Methods and Kits for Diagnosing and/or Assessing Severity and Treating Gaucher Disease — Ron Ronen, Idit, 2005, WO
- Use of Lyso-Gb1 as a Druggable Target — Centogene AG, 2022, CN
- Biomarkers of Lysosomal Storage Disease — Genzyme Corporation, 2025, CN
- Identification of a Novel Therapeutic Target Underlying Atypical Manifestation of Gaucher Disease — Asan Institute for Life Sciences, Asan Medical Center, Seoul, 2022
- Method for Normalizing Structural Abnormality of Intracellular Enzyme Protein — Kumamoto University, 2017, JP
- Gaucher Disease — GeneReviews, National Center for Biotechnology Information (NCBI)
- World Intellectual Property Organization (WIPO) — Patent Filing Norms and Rare Disease IP
- European Patent Office (EPO) — Biotechnology and Pharmaceutical Patent Resources
- National Human Genome Research Institute — Lysosomal Storage Disorders Overview
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This page represents a snapshot of innovation signals within a targeted patent and literature dataset and should not be interpreted as a comprehensive view of the full clinical pipeline or regulatory landscape.
PatSnap Eureka searches patents and research to answer instantly.